Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer
Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer
复制标题
DOI：
10.1038/sj.bjc.6601624
复制
发表时间：
2004-03-08
影响因子：
8.8
通讯作者：
Hiraki, Y
中科院分区：
文献类型：
--
作者：
Katayama, H;Ueoka, H;Hiraki, Y
本研究的目的是评估局部晚期非小细胞肺癌（LA-NSCLC）患者手术后诱导放化疗方案的可行性和有效性。共22例LA-NSCLC患者接受诱导放化疗，包括顺铂（40 mg m（-2））和多西他赛（40 mg m（-2）），在第1、8、29和36天给药，同时进行胸部放疗，剂量为40-60戈伊（2戈伊分次（-1）天（-1））。在诱导治疗完成后6周内进行手术切除。16例患者（73%）对诱导治疗有客观反应。共有20例患者（91%）接受了手术，19例患者（86%）实现了完全切除。分别在14例（64%）和5例（23%）患者中获得了病理降级和病理完全缓解。中位随访期为32个月，计算的3年总体生存率和无进展生存率分别为66%和61%。值得注意的是，14例达到病理降级的患者的3年总生存率极高（93%）。毒性可通过标准方法进行管理。未发生给药相关死亡。这种联合治疗方法在LA-NSCLC患者中是可行的，并且非常有效。这些结果需要进一步的大规模研究来证实这种方案的有效性。
The objective of this study was to assess the feasibility and effectiveness of an induction chemoradiotherapy regimen followed by surgery in patients with locally advanced non-small-cell lung cancer (LA-NSCLC). A total of 22 patients with LA-NSCLC were treated with induction chemoradiotherapy consisting of cisplatin (40 mg m(-2)) and docetaxel (40 mg m(-2)) given on days 1, 8, 29 and 36 plus concurrent thoracic irradiation at a dose of 40-60 Gy (2 Gy fraction(-1) day(-1)). Surgical resection was performed within 6 weeks after completion of induction therapy. Objective response to the induction therapy was obtained in 16 patients (73%). In all, 20 patients (91%) underwent surgery and complete resection was achieved in 19 patients (86%). Pathological downstaging and pathological complete response were obtained in 14 (64%) and five (23%) patients, respectively. With a median follow-up period of 32 months, the calculated 3-year overall and progression-free survival rates were 66 and 61%, respectively. It is noteworthy that the 3-year overall survival rate in 14 patients achieving pathological downstaging was extremely high (93%). Toxicity was manageable with standard approaches. No treatment-related deaths occurred. This combined modality treatment is feasible and highly effective in patients with LA-NSCLC. The results warrant further large-scale study to confirm the effectiveness of this regimen.